Nature Reviews Immunology (2020) https://doi.org/10.1038/s41577-020-0331-4 Published online 06 May 2020
In the originally published article, the imprecise wording of a sentence implied that IL-6 blockade had been approved by the FDA for treatment of COVID-19. This has now been corrected in the HTML and PDF versions of the article to clarify that the FDA had, at the time of writing, only approved trials of IL-6 blockade in patients with COVID-19.
About this article
Cite this article
Merad, M., Martin, J.C. Author Correction: Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. Nat Rev Immunol 20, 448 (2020). https://doi.org/10.1038/s41577-020-0353-y